Skip to content

Study · Observational study · n = 1,806 · 2019

7 results

Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study.

Mody R, Huang Q, Yu M, Patel H, Zhang X, Wang L, Grabner M

BMJ open diabetes research & care9 Dec 2019Cited by 16 (Europe PMC)

PMID31875137 (opens in a new tab)PMCIDPMC6904197 (opens in a new tab)DOI10.1136/bmjdrc-2019-000884 (opens in a new tab)PepBankPUB-31875137
Read at sourcePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In matched patients with T2D, dulaglutide was linked to greater HbA1c reduction than basal insulin (-1.12% vs -0.51%).

    In plain wordsIn patients with T2D, dulaglutide was linked to greater blood sugar improvement than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseHbA1c reduction
    Study

    n = 1,806

    Comparator
    Basal insulin
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    HbA1c change from baseline at 1 year
    −1.12%
    dulaglutide
    HbA1c change from baseline at 1 year
    −0.51%
    basal insulin

    Source sentences

    Summary
    At 1 year postindex, dulaglutide patients had significantly greater reduction in HbA1c than basal insulin (-1.12% vs -0.51%, p<0.01)
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.
  2. 02HumanObservational studyOther

    In matched patients with T2D, dulaglutide was linked to lower medical costs than basal insulin ($3753 vs $7604).

    In plain wordsIn patients with T2D, dulaglutide was linked to lower medical costs than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMedical costs
    Study

    n = 1,046

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Medical costs
    3753 USD
    dulaglutide
    Medical costs
    7604 USD
    basal insulin

    Source sentences

    Summary
    lower medical costs ($3753 vs $7604, p<0.01), higher pharmacy costs
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.
  3. 03HumanObservational studyOther

    In matched patients with T2D, dulaglutide was linked to higher pharmacy costs than basal insulin ($9809 vs $6175).

    In plain wordsIn patients with T2D, dulaglutide was linked to higher pharmacy costs than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    IncreasePharmacy costs
    Study

    n = 1,046

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Pharmacy costs
    9809 USD
    dulaglutide
    Pharmacy costs
    6175 USD
    basal insulin

    Source sentences

    Summary
    higher pharmacy costs ($9809 vs $6175, p<0.01), and similar total costs ($13 562 vs $13 779, p=0.76).
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.
  4. 04HumanObservational studyOther

    In matched patients with T2D, total costs were similar with dulaglutide and basal insulin ($13 562 vs $13 779).

    In plain wordsIn patients with T2D, total costs were similar with dulaglutide and basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changeTotal costs
    Study

    n = 1,046

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Total costs
    13,562 USD
    dulaglutide
    Total costs
    13,779 USD
    basal insulin

    Source sentences

    Summary
    and similar total costs ($13 562 vs $13 779, p=0.76).
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.
  5. 05HumanObservational studyOther

    In matched patients with T2D, medical costs per 1% HbA1c reduction were lower with dulaglutide than basal insulin ($3128 vs $12 673).

    In plain wordsIn patients with T2D, medical costs per blood sugar improvement were lower with dulaglutide than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseMedical costs per HbA1c reduction
    Study

    n = 1,046

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Medical costs per 1% HbA1c reduction
    3128 USD
    dulaglutide
    Medical costs per 1% HbA1c reduction
    12,673 USD
    basal insulin

    Source sentences

    Summary
    Medical and total costs per 1% HbA1c reduction were lower for dulaglutide than basal insulin (medical: $3128 vs $12 673, p<0.01; total: $11 302 vs $22 965, p<0.01),
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.
  6. 06HumanObservational studyOther

    In matched patients with T2D, total costs per 1% HbA1c reduction were lower with dulaglutide than basal insulin ($11 302 vs $22 965).

    In plain wordsIn patients with T2D, total costs per blood sugar improvement were lower with dulaglutide than basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    DecreaseTotal costs per HbA1c reduction
    Study

    n = 1,046

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Total costs per 1% HbA1c reduction
    11,302 USD
    dulaglutide
    Total costs per 1% HbA1c reduction
    22,965 USD
    basal insulin

    Source sentences

    Summary
    Medical and total costs per 1% HbA1c reduction were lower for dulaglutide than basal insulin (medical: $3128 vs $12 673, p<0.01; total: $11 302 vs $22 965, p<0.01),
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.
  7. 07HumanObservational studyOther

    In matched patients with T2D, pharmacy costs per 1% HbA1c reduction did not differ significantly between dulaglutide and basal insulin.

    In plain wordsIn patients with T2D, pharmacy costs per blood sugar improvement did not differ significantly between dulaglutide and basal insulin.

    Peptide
    Dulaglutide (Trulicity)
    Outcome
    No significant changePharmacy costs per HbA1c reduction
    Study

    n = 1,046

    Comparator
    Basal insulin
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Pharmacy costs per 1% HbA1c reduction
    8174 USD
    dulaglutide
    Pharmacy costs per 1% HbA1c reduction
    10,292 USD
    basal insulin

    Source sentences

    Summary
    while pharmacy costs per 1% HbA1c reduction were lower without reaching statistical significance ($8174 vs $10 292, p=0.15).
    2 context sentences
    Summary · context
    This observational claims study included patients with type 2 diabetes (T2D) and ≥1 claim for dulaglutide or basal insulin between November 2014 and April 2017 (index date=earliest fill date).
    Summary · context
    Propensity score matching was used to address treatment selection bias.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.